Clinical-stage biotechnology company Pasithea Therapeutics (NASDAQ:KTTA) entered into definitive agreements for the issuance and sale of an aggregate of ~1.22M shares and warrants at a purchase price ...
Source LinkClinical-stage biotechnology company Pasithea Therapeutics (NASDAQ:KTTA) entered into definitive agreements for the issuance and sale of an aggregate of ~1.22M shares and warrants at a purchase price ...
Source Link
Comments